TSXV:CLAS.H - Post by User
Post by
whisky11on Apr 06, 2021 7:02am
1696 Views
Post# 32939991
Sedar, Licence Agreement Nov 2020
Sedar, Licence Agreement Nov 2020 Highlights of the License Agreement
-
R-107 is a liquid prodrug of nitric oxide. Based on the fact that nitric oxide is an approved treatment for acute respiratory failure in newborns, and the clinical evidence of nitric oxide’s antiviral activity against strains of coronavirus, Salzman Group will develop R-107 for treatment of coronavirus and COVID-19 associated lung infection.
-
Following completion of a Phase 1 clinical safety and pharmacokinetic study, Kalytera intends to apply for funding from the U.S. Department of Health and Human Services for the costs of Phase 2 and Phase 3 clinical studies of R-107 in coronavirus and COVID-19 infection.
-
If the application for a new BARDA contract for development of R-107 for treatment of coronavirus and COVID-19 infection is successful, Salzman Group may receive an additional USD $20 million under this BARDA contract.
-
Kalytera expects the Phase 1 clinical safety and pharmacokinetic study to be completed in the first half of 2021.
-
Under the terms of the License Agreement, Kalytera will pay a $1.2 million cash license fee to Salzman Group, and also issue to the former shareholders of Salzman Group 130 million Kalytera common shares. As of September 30, 2020, Kalytera has made partial payments of the $1.2 million cash license fee to the former shareholders of Salzman Group in the total amount of approximately $541,000.